TY  - JOUR
AU  - Vergote, Ignace
AU  - Ray-Coquard, Isabelle
AU  - Anderson, Daniel M
AU  - Cantuaria, Guilherme
AU  - Colombo, Nicoletta
AU  - Garnier-Tixidre, Claire
AU  - Gilbert, Lucy
AU  - Harter, Philipp
AU  - Hettle, Robert
AU  - Lorusso, Domenica
AU  - Mäenpää, Johanna
AU  - Marth, Christian
AU  - Matsumoto, Koji
AU  - Ouwens, Mario
AU  - Poveda, Andrés
AU  - Raspagliesi, Francesco
AU  - Rhodes, Kirsty
AU  - Rubio Pérez, María J
AU  - Shapira-Frommer, Ronnie
AU  - Shikama, Ayumi
AU  - Sikorska, Magdalena
AU  - Moore, Kathleen
AU  - DiSilvestro, Paul
PY  - 2021
DO  - 10.1016/j.ejca.2021.08.023
UR  - http://hdl.handle.net/10668/18587
T2  - European journal of cancer (Oxford, England : 1990)
AB  - In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone and in...
LA  - en
KW  - BRCA mutation
KW  - Bevacizumab
KW  - Newly diagnosed
KW  - Olaparib
KW  - Ovarian cancer
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - BRCA1 Protein
KW  - BRCA2 Protein
KW  - Bevacizumab
KW  - Double-Blind Method
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Maintenance Chemotherapy
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Staging
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - Piperazines
KW  - Placebos
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Progression-Free Survival
KW  - Response Evaluation Criteria in Solid Tumors
TI  - Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
TY  - research article
VL  - 157
ER  -